Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (review)
Irinotecan, oxaliplatin and raltitrexed for advanced colorectal cancer (review of TA33)
| Guidance type: Technology appraisal |
| Date issued: August 2005 |
We will consult on our review plans for this guidance in August 2008. |
| Reference: TA93 |
SummaryIrinotecan and oxaliplatin are recommended as possible treatments for people with advanced colorectal cancer, if they are used in these ways:
Raltitrexed is not recommended for people with advanced colorectal cancer, unless they are taking part in a clinical trial. This guidance replaces TA33 Colorectal cancer (advanced) – irinotecan, oxaliplatin and raltitrexed. |
| Top |
DocumentsFor healthcare professionals
For patients, carers and the publicBackground information |
Implementing this guidanceAny further information NICE has produced to help the NHS implement this guideline locally is linked to below:
|
| Top |
